Receptor News and Research

RSS

Study reveals how leukemia cells invade lungs and cause breathing problems

Led by NYU Langone Health researchers, a new study shows how blood cancer cells enter the lungs, damage tissue, and cause severe breathing problems.

29 Jun 2026

Simple blood test could identify the most effective obesity drug

Fasting blood tests measuring GLP-1 and GIP levels may predict obesity treatment response to semaglutide and tirzepatide, enhancing personalized therapy.

29 Jun 2026

Melatonin dampens fetal membrane inflammation linked to preterm birth

Melatonin reduced infection-related inflammation in human fetal membranes in an ex vivo model. The study suggests that this effect works partly through melatonin receptors and by suppressing the TLR4/MyD88/NF-κB pathway.

28 Jun 2026

Scientists uncover immune mechanisms driving rare gastrointestinal disorder

A collaborative team led by Dr. Jingnan Li and Dr. Ji Li at Peking Union Medical College Hospital, together with Associate Professor Xiaohuan Guo at Tsinghua University and Academician Ye-Guang Chen at Tsinghua University School of Life Sciences, published a study in Volume 2, article number 28 of the journal Immunity & Inflammation on June 17, 2026.

26 Jun 2026

Engineered CAR T cells successfully target bladder cancer in mice

Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center, and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells.

26 Jun 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

Gut microbes emerge as potential players in estrogen-driven cancers

A new review maps how the endocrine-microbiome axis expands the estrobolome concept, showing that gut microbes may alter estrogen recycling, produce hormone-like metabolites, and shape inflammation and tissue environments in hormone-driven cancers. Human evidence remains mostly associative, so the authors call for causal models, longitudinal multi-omics, multi-kingdom profiling, and sex-stratified studies before microbiome-guided cancer strategies enter routine care.

25 Jun 2026

Cone opsin structures offer insights into vision loss

The retina of the human eye contains six to seven million cone cells. These cells contain light-sensitive proteins known as cone opsins.

25 Jun 2026

Natural compound puerarin may protect against cholestatic liver fibrosis

A recent study published in Current Molecular Pharmacology demonstrates that puerarin-a bioactive isoflavone derived from Kudzu root and widely used in traditional Chinese medicine-may offer significant therapeutic benefits against cholestatic liver fibrosis, a progressive pathological condition arising from impaired bile formation and flow that currently lacks effective pharmacotherapies.

25 Jun 2026

Exercise, not liraglutide alone, drives vascular gains after obesity-related weight loss

A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and circulating levels of inflammatory cytokines in adults with obesity who had already achieved substantial diet-induced weight loss. Liraglutide alone did not significantly improve these vascular or inflammatory markers, while exercise plus liraglutide also improved endothelial function biomarkers.

25 Jun 2026

Researchers develop novel strategy to selectively target tumor microenvironments

A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR and other kinases with controlled release in tumor microenvironments to improve therapeutic efficacy, with promising results.

25 Jun 2026

New review highlights TREM-1 receptor as target for inflammatory diseases

A comprehensive review recently published in Current Molecular Pharmacology consolidates the growing evidence surrounding the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a central amplifier of innate immune responses and a promising therapeutic target for a range of inflammatory diseases.

25 Jun 2026

Chronic stress helps tumors evade immune attack through gut microbes

Chronic psychological stress can help tumors evade immune attack through a chain of molecular events involving gut bacteria and viruses within those bacteria, according to a study led by Weill Cornell Medicine investigators.

25 Jun 2026

Gene linked to lower BMI points researchers toward a new obesity target

A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.

25 Jun 2026

FDA approves palbociclib combination for advanced HR-positive HER2-positive breast cancer

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for adult patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) locally advanced or metastatic breast cancer following induction treatment.

24 Jun 2026